Rainbow 60™ - Familial and Common Cancer Risk Assessment Test
Cancer genetic predisposition is genetic variation typically inherited from a patient's parent, and increases the likelihood of developing a cancer. Certain mutations can greatly increase the risk of developing cancers while others may have much smaller effects. For example, mutations in cancer predisposition genes are associated with 3% to 5% of breast and colorectal cancers, and as much as 15% of ovarian cancer.
Exome sequencing test can determine if a patient has increased risk of multiple types of cancers. This increased risk can often be managed by monitoring, preventive medication or even prophylactic surgery. Family members of an individual who carries a pathogenic cancer mutation may also consider testing to clarify their own risk.
Determination of a familial cancer (germline) mutation in a cancer predisposition gene may guide treatment of the cancer patient. For examples, oncologists may consider colectomy for colorectal cancer and Lynch syndrome patients, or PARP inhibitor as treatment for an ovarian cancer patient with a BRCA1/2 mutation, or elimination of radiation in a breast cancer patient with a TP53 mutation. (see ASCO web resource below for more information)
Baylor Genetics. This test was developed in collaboration with Baylor Genetics, the genetic laboratory associated with Baylor College of Medicine. Baylor is one of the oldest and largest genetic testing and medical institutions in the U.S., and is a leader in cancer screening and diagnosis.
Rainbow Wellness Cancer™ Test
Screening test. The Rainbow Wellness Cancer test screens for genetic variations in 118 genes, covering over 20 types of cancers, including breast, ovarian, lung, colorectal, prostate, gastric and pancreatic cancers. This is a multi-cancer screening test designed for healthy individuals without cancer symptoms or family histories.
Common Cancer Risk Assessment Test. Your sample will also be sent to Korea-based Macrogen for population-based, common genetic risk assessment on seven common cancers.
The process starts with a physician office visit at a Rainbow-authorized clinic. The clinician will order the test for the patient. Clinical whole exome sequencing at mean 100X-150X coverage is performed at CAP-accredited or CLIA-certified laboratories. Data will be analyzed and clinically interpreted under ACMG guidelines by Baylor Genetics, and a physician report will be issued by a Baylor Genetics board-certified medical director.
Risk assessment test for seven common cancers is performed using current genotyping technologies by Macrogen. Clinical report is signed off by three laboratory and quality control directors from Macrogen.
Hereditary Cancers Screened (20)
1. Breast 2. Ovarian 3. Colorectal 4. Lung
5. Prostate 6. Uterine 7. Gastric 8. Pancreatic
9. Thyroid 10. Melanoma
11. Renal 12. Urinary Track
13. Central & Peripheral Nervous System Cancers
14. Paraganglioma 15. Pheochromocytoma
16. Brain 17. Sarcoma
18. Neuroendocrine 19. Leukemia
20. Myelodysplastic Syndrome
Common Cancers Screened (7)
Lung, Bladder, Thyroid, Testicular, Esophageal, Kidney & Liver Cancers.
Rare Cancers Screened (33)
Ataxia-telangiectasia (A-T). Bloom syndrome. Carney complex.
Multiple endocrine neoplasia type 1, Type 2 (MEN1, MEN2). Costello syndrome.
Cowden and Cowden-like syndrome.
DICER1 syndrome. Dyskeratosis congenita. Neurofibromatosis type 2 (NF2).
Neurofibromatosis type 1 (NF1).
Familial acute myeloid leukemia (AML) syndrome. Nevoid basal cell carcinoma – also known as Gorlin syndrome.
Familial adenomatous polyposis (FAP). Nijmegen breakage syndrome (NBS).
Familial gastrointestinal stromal tumors (GIST). Oligodontia-colorectal cancer syndrome.
Familial neuroblastoma. Hereditary paraganglioma-pheochromocytoma.
Familial platelet disorder with propensity to myeloid malignancy (FPD/AML)
Perlman syndrome. GATA2 deficiency. Peutz-Jeghers syndrome (PJS)
Rhabdoid tumor predisposition syndrome (RTPS). Hereditary Lung Cancer
Simpson-Golabi-Behmel syndrome (SGBS). Hereditary papillary renal cell carcinoma.
Tuberous sclerosis complex (TSC). Hereditary paraganglioma-pheochromocytoma syndrome (PGL/PCC).
von Hippel-Lindau syndrome (VHL). Juvenile polyposis syndrome (JPS).
Werner syndromeLi-Fraumeni syndrome (LFS). Wilms tumor-related conditions
Is This Test Right For You?
The Rainbow Wellness Cancer test is designed for healthy individuals who would like to understand their future risk of developing hereditary cancers.
If you already have cancer symptoms or a family history that suggests an inherited cancer risk condition, or you have several close relatives with the same type of cancer, you should consult with your physician to order the Rainbow High-Risk Cancer test, which is designed as a diagnostic test based on your symptoms and family history.